Veristat
Research ServicesMassachusetts, United States201-500 Employees
Veristat is a science-first contract research organization and consultancy that provides end-to-end support for drug and biologic development, uniting strategic planning, regulatory expertise, and clinical trial execution to advance complex therapies. The company works with clients to enable rapid delivery of therapies and to navigate uncertainty in decision-making, with its scientific experts designing and conducting global activities across clinical, regulatory, and commercialization programs. With nearly 30 years of experience and a versatile, rigorous approach to science, Veristat concentrates on novel drug development and aims to enable progress in areas such as rare cancers, CNS and neurological disorders, endocrine and metabolic diseases, and infectious diseases. Headquartered in Southborough, Massachusetts, Veristat positions itself as a mid-sized CRO focused on supporting biotechnology and pharmaceutical programs through specialized development work. In January 2026, the company named Kim McLean Boericke as Chief Executive Officer, reflecting a leadership transition.